NHS denied £2m of savings after hydrocortisone suppliers enter anticompetitive agreements, finds CMA
Auden Mckenzie and Waymade have been provisionally found to have broken competition law, the UK’s Competition and Markets Authority has found.
The NHS was denied potential savings on hydrocortisone tablets after two suppliers entered into anticompetitive agreements, the Competition and Markets Authority (CMA) has provisionally found.
From July 2011 to April 2015, Auden Mckenzie remained the sole supplier of 20mg hydrocortisone tablets, despite Waymade, another supplier, being ready to enter the market in May 2011 with the same tablets.
Instead, the CMA found that Waymade froze its stock and struck a deal with Auden Mckenzie to receive monthly payments in return for delaying its entry into the market.
The CMA found that between 2011 and 2015 the price of 20mg hydrocortisone tablets increased from around £46 to £90 for a pack of 30 tablets, increasing the annual costs incurred by the NHS for the medicine from £1.7m to £3.7m.
According to the CMA’s provisional findings, Waymade also obtained a licence to sell 10mg hydrocortisone tablets in September 2012 and, in exchange for Waymade not entering the market, Auden Mckenzie allegedly lowered the price it charged Waymade from the market rate of around £32 per pack to £1.
Michael Grenfell, the CMA’s executive director for enforcement, said: “The CMA has today provisionally found that Auden Mckenzie and Waymade broke competition law through Auden Mckenzie paying its rival to stay out of the market.
“Hydrocortisone is a life-saving drug for those [living] with Addison’s Disease in the UK. The NHS should not be denied the opportunity of benefitting from an increased choice of suppliers and potential savings on what it spends on this essential drug.”
Vijay Patel, the director of Waymade and a pharmacist, was awarded an OBE in the New Year’s Honours list for his services to business and philanthropy.
Following this provisional finding, the companies will now be able to state their case to the CMA before it reaches a final decision.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206236
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.£33.00Buy now